NeoGenomics, Inc., incorporated on October 29, 1998, is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. The Company offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation.
The Company's Cytogenetics testing is the study of normal and abnormal chromosomes and the relationship to disease, which involves looking at the chromosome structure to identify changes from patterns seen in normal chromosomes. The FISH testing is a branch of cancer genetics that focus on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes, and can be used to help identify a number of gene alternations, such as amplification, deletions and translocations. The flow cytometry testing a rapid way to measure the characteristics of cell populations. Cells from peripheral blood, bone marrow aspirate, lymph nodes and other areas are labeled with selective fluorescent antibodies and analyzed as they flow in a fluid stream through a beam of light. Flow cytometry is performed in diagnosing a range of leukemia and lymphoma neoplasms. Flow cytometry is also used to monitor patients through therapy to determine whether the disease burden is increasing or decreasing, otherwise known as minimal residual disease monitoring. The IHC and digital imaging refers to the process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues. IHC is used in the diagnosis of abnormal cells, such as those found in cancerous tumors. The Molecular testing is a rapidly growing cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA), as well as the structure and function of genes at the molecular level. The Pathology consultation services provided for clients in which its pathologists review surgical samples on a consultative basis.
The Company' Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data. In other pre and non-clinical work, it can use its platforms to characterize markers of interest. Moving from discovery to development, it helps its customers refine their biomarker strategy and, if applicable, develop a companion diagnostic pathway using the optimal technology for large-scale clinical trial testing.
The Company performs analyses for hematopoietic cancers, such as leukemia and lymphoma (blood and lymphoid tumors) and solid tumor cancers, such as breast, lung, colon and bladder cancer. The Company offers its testing services to hospitals, pathologists, oncologists, other clinicians and researchers.
The Company competes with Quest Diagnostics and Laboratory Corporation of America.
12701 Commonwealth Dr Ste 9
The company trades on NASDAQ exchange. The company headquarter is located in Florida, FL. The company was established in the 2001.| Ticker | NEO |
| Long Name | NeoGenomics, Inc. |
| Short Name | NeoGenomics |